EXTENDED RELEASE FORMULATION CONTAINING TOFACITINIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN ACTIVE INGREDIENT AND THE PREPARATION METHOD FOR THE SAME
The present invention relates to a sustained-release preparation comprising tofacitinib or a pharmaceutically acceptable salt, sustained release agent and hydrophilic binder thereof, and a content of a sustained-release preparation in vivo at a content of 10 mg, which is less than the sustained-release product currently on the market. Disclosed is a sustained release formulation of a hydrophilic matrix formulation that exhibits an equivalent effect and has a relatively simple manufacturing process, which is excellent in productivity and economy.본 발명은 토파시티닙 또는 그의 약제학적으로 허용되는 염, 서방화제 및 친수성 결합제를 포함하는 서방성 제제에 관한 것으로, 현재 시판중인 서방성 제품보다 적은 함량 즉, 10mg으로 생체내에서 속방성 제제와 동등한 효과를 나타내며, 제조 과정이 비교적 간단하여 생산성 및 경제성이 우수한 친수성 매트릭스 제형의 서방성 제제를 개시한다.
